Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | PLEC | Q15149 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2463214 | 0.94 | KDM4E (0.54) | KDM4EHTTLMNAMEN1KMT2A | |
| SCHEMBL9901537 | 0.94 | KDM4E (0.54) | KDM4EHTTLMNAMEN1KMT2A | |
| SCHEMBL9901513 | 0.92 | ALDH1A1 (0.39) | KDM4EHTTLMNAMEN1KMT2A | |
| SCHEMBL2466004 | 0.92 | ALDH1A1 (0.42) | KDM4EHTTLMNAMEN1KMT2A | |
| SCHEMBL2462948 | 0.92 | ALDH1A1 (0.42) | KDM4EHTTLMNAMEN1KMT2A | |
| SCHEMBL2465646 | 0.90 | CRHR1 (0.38) | KDM4EHTTLMNAMEN1KMT2A | |
| SCHEMBL9900882 | 0.90 | CRHR1 (0.38) | KDM4EHTTLMNAMEN1KMT2A | |
| SCHEMBL2465393 | 0.89 | ALDH3A1 (0.44) | KDM4EHTTLMNAMEN1KMT2A | |
| SCHEMBL2489167 | 0.87 | KDM4E (0.45) | KDM4EHTTLMNAMEN1KMT2A | |
| SCHEMBL2464566 | 0.86 | KDM4E (0.39) | KDM4EHTTLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4616069-A | REACTING THE ALKALI METAL OR ALKALINE EARTH METAL TERMINATED POLYMER WITH TIN COMPOUND AND ORGANIC COMPOUND HAVING AMIDE OR THIOAMIDE LINKAGES | NIPPON ZEON CO., LTD. (JP) | 1986-10-07 | — | — | US | claimed |
| US-4614771-A | POLYMERIZATION WITH AROMATIC VINYL MONOMER AND ALKALINE(OR ALKALINE EARTH) METAL, THEN MINO(OR AMINOTHIO)ALDEHYDES OR KETONES | NIPPON ZEON CO., LTD. (JP) | 1986-09-30 | — | — | US | claimed |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2016-05-12 | — | — | US | disclosed |
| US-9173886-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TRANA DISCOVERY, INC (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2011113060-A2 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| EP-0572792-B1 | Tire tread composition | BRIDGESTONE CORP (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0572792-A1 | Tire tread composition | BRIDGESTONE CORPORATION (JP) | 1993-12-08 | — | — | EP | disclosed |
| US-5248722-A | Functionalized elastomer, oxidized carbon black, reduced hysteresis | BRIDGESTONE CORPORATION (JP) | 1993-09-28 | — | — | US | disclosed |
| EP-0180853-B1 | PROCESS FOR MAKING DIENE COPOLYMER RUBBERS | NIPPON ZEON CO., LTD. (JP) | 1989-10-04 | — | — | EP | disclosed |
| US-4616069-A | REACTING THE ALKALI METAL OR ALKALINE EARTH METAL TERMINATED POLYMER WITH TIN COMPOUND AND ORGANIC COMPOUND HAVING AMIDE OR THIOAMIDE LINKAGES | NIPPON ZEON CO., LTD. (JP) | 1986-10-07 | — | — | US | disclosed |
| US-4614771-A | POLYMERIZATION WITH AROMATIC VINYL MONOMER AND ALKALINE(OR ALKALINE EARTH) METAL, THEN MINO(OR AMINOTHIO)ALDEHYDES OR KETONES | NIPPON ZEON CO., LTD. (JP) | 1986-09-30 | — | — | US | disclosed |
| EP-0180853-A1 | Process for making diene copolymer rubbers | NIPPON ZEON CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180141-A1 | Process for making diene polymer rubbers | NIPPON ZEON CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TYMP, MAVS, ZC3HAV1 | KDM4E 1881/4885HTT 1289/4885LMNA 2558/4885 |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | KDM4E 1881/4885HTT 1289/4885LMNA 2558/4885 |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TYMP, MAVS, ZC3HAV1 | KDM4E 1881/4885HTT 1289/4885LMNA 2558/4885 |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | KDM4E 1881/4885HTT 1289/4885LMNA 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.